Related Experiment Video
Updated: Aug 8, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug type contributions to pharmaceutical innovation: A USA-China comparative analysis
Michael S Kinch1, Aayan Alwani1, Tyler Schwartz2
1Department of Pharmaceutical Sciences, Stony Brook University, Stony Brook, NY, USA.
None:
An analysis of experimental medicines entering clinical trials from 2000 to 2024 reveals divergent patterns of development activity between the USA and China. Whereas China's ascent was consistent in the most common therapeutic category: small molecules, its rise was most pronounced in biologics-oriented categories, particularly cell therapy and monoclonal antibodies. By contrast, the USA retained comparatively greater shares in emerging modalities such as nucleic acid therapeutics and gene therapy. These findings add resolution to the phenomenon of Chinese near-parity with the USA in overall pharmaceutical output. The convergence is not uniform across modalities but instead reflects differential growth by drug type. Causal attribution of these patterns to specific policy or investment decisions warrants further investigation.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Drug Nomenclature
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Bioequivalence studies: Biowaivers
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...